Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05093205 · ClinicalTrials.gov registry record · Phase 1
Study TO Evaluate THE Effect OF PF-06882961 ON Single Dose Atorvastatin, Medazolam AND Oralcontraceptive Pharmacokinetics IN Healthy Adult Participants
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT05093205 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 35 participants.
The verdict
NCT05093205, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the effect of PF-06882961, administered at 2 steady-state dose levels, on the PK of single doses of atorvastatin (20 mg) or midazolam (5 mg), administered separately, in healthy adult male and female participants (Part A), or an OC in healthy PM female participants (Part B).
Interventions
- DRUG Midazolam
- DRUG Atorvastatin
- DRUG PF-06882961
- DRUG Levonorgestrel & Ethinyl Estradiol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2021-10-25 |
| Est. Completion | 2022-07-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05093205
The ClinicalTrials.gov registry entry for NCT05093205 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Midazolam is the first listed.
NCT05093205 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05093205 about?
NCT05093205 is a clinical study titled "Study TO Evaluate THE Effect OF PF-06882961 ON Single Dose Atorvastatin, Medazolam AND Oralcontraceptive Pharmacokinetics IN Healthy Adult Participants". The purpose of this study is to characterize the effect of PF-06882961, administered at 2 steady-state dose levels, on the PK of single doses of atorvastatin (20 mg) or midazolam (5 mg), administered separately, in healthy adult male and female participants (Part A), or an OC in healthy PM female pa...
What is the current status of trial NCT05093205?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2021-10-25. Estimated completion is 2022-07-06.
What interventions are being tested in trial NCT05093205?
The interventions under investigation include: Midazolam (DRUG), Atorvastatin (DRUG), PF-06882961 (DRUG), Levonorgestrel & Ethinyl Estradiol (DRUG).
Who is sponsoring clinical trial NCT05093205?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.